Please assess the completion status of the following clinical trial:

Trial Title: Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients \> 45 years~* Damage of the optic nerve and alterations of the visual field in case of POAG, no defects at the optic nerve and at the visual field in case of OHT~* Untreated IOP \> 24 mm Hg but \< 32 mm Hg in at least one eye at baseline (10AM) and central corneal thickness between 500 and 600 μm~* Negative pregnancy test (fertile women). Fertile women attending the study must express clear will to avoid pregnancy during all the study period and in the next three months~* Informed consent before starting the study~Exclusion Criteria:~* Secondary glaucoma (Sturge-Weber syndrome, Neurofibromatosis I, neovascular glaucoma, steroid glaucoma, etc)~* Anterior segment anomalies (cataract, irido-corneal disgenesy, congenital ectropion uvae, etc)~* Past ocular surgery, except cataract surgery in the previous 6 months~* Corneal abnormalities that can influence IOP measurements (corneal oedema)~* Positive pregnancy test or breast-feeding woman. No will to avoid pregnancy during all the study period and in the next three months

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAFLUPROST 0.0015% EYEDROPS (Type: EXPERIMENTAL): Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
- LATANOPROST 0.005% EYEDROPS (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.

Based on this trial design, predict the completion outcome and termination type (if applicable).